Common Contracts

EXECUTION VERSION CONFIDENTIAL TREATMENT REQUESTED. INFORMATION FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED IS OMITTED AND MARKED WITH “[*******]” OR OTHERWISE CLEARLY INDICATED. AN UNREDACTED VERSION OF THIS DOCUMENT HAS ALSO BEEN PROVIDED TO...

Distribution and Sublicense Agreement • May 5th, 2020 • New York

• Contract Type
  Distribution and Sublicense Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  New York

THIS DISTRIBUTION AND SUBLICENSE AGREEMENT (this “Agreement”), dated as of February 1, 2016 (the “Effective Date”), by and between Braeburn Pharmaceuticals, inc., a corporation formed under the laws of Delaware (“Braeburn”), and Knight Therapeutics Inc., a corporation incorporated under the laws of Canada (“Knight”).

DISTRIBUTION AND SUBLICENSE AGREEMENT

Distribution and Sublicense Agreement • August 14th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York

• Contract Type
  Distribution and Sublicense Agreement
• Filed
  August 14th, 2018
• Company
  Titan Pharmaceuticals Inc
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  New York

THIS DISTRIBUTION AND SUBLICENSE AGREEMENT (this “Agreement”), dated as of February 1, 2016 (the “Effective Date”), by and between Braeburn Pharmaceuticals, inc., a corporation formed under the laws of Delaware (“Braeburn”), and Knight Therapeutics Inc., a corporation incorporated under the laws of Canada (“Knight”).